Table 2.

Meta-analysis results of the association between expression of TOP2A, amplification or alteration of TOP2A and cancer prognosis for pooled HR.

Comparison	Categories	Group/subgroup	Data set number	HR(95%CI)	P value	Model	P value	I² (%)
Expression (High vs. Low)	OS	Overall	12	1.25(0.91-1.71)	0.163	R	<0.001	71.20%
		Europe	4	1.38(1.10-1.73)	0.005	F	0.068	57.90%
		Australia	5	1.48(0.79-2.78)	0.218	R	<0.001	81.50%
	DFS	Overall	11	1.36(1.18-1.57)	<0.001	F	0.137	32.80%
		Europe	6	1.28(1.07-1.52)	0.007	F	0.257	23.60%
		Australia	3	1.80(1.07-3.04)	0.028	R	0.044	67.90%
Amplification(Amp vs. non-Amp)	OS	Overall	13	0.96(0.75-1.22)	0.735	R	0.003	59.40%
		Europe	8	1.07(0.80-1.45)	0.644	R	0.007	64.10%
		Australia	3	0.66(0.46-0.96)	0.029	F	0.115	53.80%
	DFS	Overall	5	0.93(0.70-1.23)	0.621	F	0.072	53.60%
	RFS	Overall	4	0.97(0.71-1.34)	0.867	R	0.036	64.80%
Alteration (Altered vs. Normal)	OS	Overall	4	1.37(1.22-1.55)	<0.001	F	0.238	28.90%
	RFS	Overall	4	1.26(1.12-1.41)	<0.001	F	0.191	36.90%

R: random effect model; F: fixed effect model; OS: overall survival; DFS: disease free survival; RFS: relapse free survival